Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

241
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
241
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

251
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
251
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

209
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
209

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and validation of an intra-tumoral and peri-tumoral radiomics model based on dynamic contrast-enhanced ultrasound for predicting lymph node metastasis in type 2 diabetic patients with thyroid cancer.

Frontiers in endocrinology·2026
Same author

High proportion of peripheral blood and haploidentical stem cell transplantation in Chinese children: a nationwide CCBMTR analysis.

Bone marrow transplantation·2026
Same author

ENO1 promotes acute myeloid leukemia progression through SCD1-mediated lipid metabolism reprogramming.

Blood advances·2026
Same author

Thymidine-Auxotrophic Salmonella Enables Selective Tumor Colonization and Adenosine Depletion for Cancer Immunotherapy.

Advanced materials (Deerfield Beach, Fla.)·2026
Same author

Non-specific Clones Hamper the Reliability of Immunoglobulin Light Chain Gene Rearrangements in Next-Generation Sequencing-Based Measurable Residual Disease Monitoring in Pediatric B-Cell Acute Lymphoblastic Leukemia: A Single-Center Cohort Study.

Annals of laboratory medicine·2026
Same author

Clinical Characteristics and Prognostic Risk Factors for Pediatric B-Cell Lymphoblastic Lymphoma: A Multicenter Retrospective Cohort Study for China Net Childhood Lymphoma.

Pediatric blood & cancer·2026

Related Experiment Video

Updated: Jan 14, 2026

Involving Individuals with Developmental Language Disorder and Their Parents/Carers in Research Priority Setting
06:16

Involving Individuals with Developmental Language Disorder and Their Parents/Carers in Research Priority Setting

Published on: June 6, 2020

4.2K

Risk factors for DIC in paediatric APL: Insights from the CCLG-APL 2016 study.

Qingyuan Xu1, Linya Wang1, Shaoyan Hu2

  • 1Hematology Center, National Key Discipline of Pediatric Hematology, National Key Discipline of Pediatrics (Capital Medical University); Key Laboratory of Major Diseases in Children, Ministry of Education; Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, Xicheng District, China.

British Journal of Haematology
|October 23, 2025
PubMed
Summary

Low initial platelet counts increase the risk of disseminated intravascular coagulation (DIC) in children with acute promyelocytic leukemia (APL). Realgar-indigo naturalis formula (RIF) therapy shows protective effects against DIC.

Keywords:
APLDICpaediatricrisk factors

More Related Videos

A Pediatric Concussion Model in Mice: Closed Head Injury with Long-Term Disorders (CHILD)
07:01

A Pediatric Concussion Model in Mice: Closed Head Injury with Long-Term Disorders (CHILD)

Published on: February 7, 2025

857

Related Experiment Videos

Last Updated: Jan 14, 2026

Involving Individuals with Developmental Language Disorder and Their Parents/Carers in Research Priority Setting
06:16

Involving Individuals with Developmental Language Disorder and Their Parents/Carers in Research Priority Setting

Published on: June 6, 2020

4.2K
A Pediatric Concussion Model in Mice: Closed Head Injury with Long-Term Disorders (CHILD)
07:01

A Pediatric Concussion Model in Mice: Closed Head Injury with Long-Term Disorders (CHILD)

Published on: February 7, 2025

857

Area of Science:

  • Pediatric Hematology Oncology
  • Leukemia Research
  • Coagulation Disorders

Background:

  • Disseminated intravascular coagulation (DIC) is a severe complication in pediatric acute promyelocytic leukemia (APL).
  • Identifying early risk factors for DIC is crucial for timely intervention and improved patient outcomes.
  • Understanding the role of specific genetic mutations and treatment modalities in DIC development is essential.

Purpose of the Study:

  • To identify early risk factors for DIC, especially severe grades (4-5), in pediatric APL patients undergoing induction therapy.
  • To evaluate the impact of initial patient characteristics and treatment regimens on DIC occurrence and severity.
  • To compare the efficacy of arsenic trioxide (ATO) and realgar-indigo naturalis formula (RIF) in preventing DIC.

Main Methods:

  • A cohort of 186 pediatric APL patients from the CCLG-APL 2016 study was analyzed.
  • Patients were categorized based on the occurrence and severity of DIC during induction therapy.
  • Multivariate analysis was employed to identify independent risk factors and protective factors for DIC.

Main Results:

  • DIC occurred in 52.2% of patients, with 7.5% experiencing grade 4-5 DIC.
  • Initial low platelets (PLT ≤26×10^9/L) were an independent risk factor for DIC (OR=2.679).
  • Realgar-indigo naturalis formula (RIF) induction therapy demonstrated a protective effect (OR=0.465).
  • For grade 4-5 DIC, independent risk factors included FLT3 mutation (OR=11.742), initial PLT ≤26×10^9/L (OR=13.784), and initial bone marrow blasts ≥90% (OR=5.289).

Conclusions:

  • Initial low platelet count is a significant independent risk factor for DIC in pediatric APL.
  • RIF therapy may serve as a protective factor against DIC during induction therapy.
  • FLT3 mutation, very low initial platelet count, and high bone marrow blast percentage are critical risk factors for severe DIC in pediatric APL.